Evidence map›Paper›PMID 42086534›Full record

ArticleCell death & disease2026

Correction: SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer.

Min Tang, Luotong Xue, Bao Wang, Zhixin Jiang, Pu Li, Hengtao Bu, Chesong Zhao, Yurong Zhang, Shuaimei Liu, Xiyuan Chen and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Min Tang *Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Luotong Xue *Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Bao Wang *Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Zhixin Jiang *NHC Key Laboratory of Contraceptives Vigilance and Fertility Surveillance, Nanjing, Jiangsu, China.
Pu LiDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Hengtao BuDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Chesong ZhaoDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Yurong ZhangDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Shuaimei LiuNHC Key Laboratory of Contraceptives Vigilance and Fertility Surveillance, Nanjing, Jiangsu, China.
Xiyuan ChenDepartment of Urology, Shuyang Hospital, Suqian, Jiangsu, China.
Bianjiang LiuDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. bjliu@njmu.edu.cn.ORCID http://orcid.org/0000-0002-4705-6445
Xiaoxin MengDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. mengxiaoxin@126.com.
Jie LiDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. lijie203075@yahoo.com.ORCID http://orcid.org/0009-0007-9621-9590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42086534
PMCPMC13144503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.